Cover Image
市場調查報告書

乾癬:美國的醫藥品市場預測與分析

Psoriasis - US Drug Forecast and Market Analysis to 2024

出版商 GlobalData 商品編碼 365841
出版日期 內容資訊 英文 213 Pages
訂單完成後即時交付
價格
Back to Top
乾癬:美國的醫藥品市場預測與分析 Psoriasis - US Drug Forecast and Market Analysis to 2024
出版日期: 2016年04月13日 內容資訊: 英文 213 Pages
簡介

本報告提供美國的乾癬治療藥臨床實驗趨勢與上市預測相關分析,乾癬概要 (病因、病理、症狀、診斷方法等) ,及目前的主要的治療方法,現在臨床實驗中/已上市的開發中產品的概要 (功效,SWOT分析等),市場規模預測 (今後11年份),主要的推動市場要素與其影響度等相關的調查評估。

第1章 目錄

第2章 簡介

  • 分析的背景情況
  • 相關報告
  • 近日出版的相關報告

第3章 疾病概要

  • 病因與病情
    • 病因
    • 病理生理學
  • 症狀

第4章 疾病管理

  • 診斷、治療方法概要
    • 診斷
    • 代表性處方藥和治療指南
    • 臨床診療
  • 美國

第5章 競爭力的評估

  • 概要
  • 競爭企業的策略性評估
  • 產品簡介:領導品牌
    • Enbrel (Etanercept)
    • Humira (Adalimumab)
    • Remicade (Infliximab)
    • Stelara (Ustekinumab)
    • Cosentyx (secukinumab)
    • Otezla (apremilast)
    • Taclonex及Enstilar (Calcipotriene及Betamethasone Dipropionate)
    • Methotrexate
    • Fumaderm (富馬酸酯)
    • Alzumab (itolizumab)
    • 疥瘡治療所利用的其他治療藥物類型
    • 非藥物治療

第6章 未滿足需求與市場機會

  • 概要
  • 醫藥品取向醫療費償付模式,造成的患者取用的限制
    • 未滿足需求
    • 差距分析
    • 市場機會
  • 醫藥品的安全性、功效簡介的改善
  • 乾癬附隨的心理要素相關教育與治療
  • (不僅是斑塊型乾癬)各種乾癬相關醫學教育

第7章 開發中產品的評估

  • 概要
  • 臨床實驗製圖
    • 各國臨床實驗趨勢
  • 各相位、各階段臨床實驗趨勢
  • 臨床實驗階段的有希望醫藥品
    • Xeljanz (Tofacitinib)
    • Ixekizumab (LY2439821)
    • Brodalumab
    • Guselkumab (CNTO-1959)
    • Tildrakizumab
    • Piclidenoson (CF-101)
    • 額外的第三階段開發中產品
    • 第二階段的開發中產品
    • 第一階段的開發中產品
  • 開發平台上的生技仿製藥產品
    • 簡介
    • 對於主要的自體免疫疾病,Inflectra (Hospira) 和Versus J&J (Versus J&J) 的功效比較
    • 免疫學界中生技仿製藥的滲透
    • 開發中的生技仿製藥的數量
    • 對製藥產業的生技仿製藥的影響度
    • 乾癬治療的生技仿製藥的普及度,預計依市場而不同
    • 生技仿製藥市場預測

第8章 市場未來展望

  • 美國
    • 預測
    • 近幾年主要的事件
    • 市場促進、阻礙因素

第9章 附錄

圖表一覽

目錄
Product Code: GDHC278CFR

Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide. Specifically, adult plaque psoriasis, the most common form of Psoriasis, is the focus of this report. Although not life-threatening, Psoriasis causes tremendous morbidity and personal angst for patients.

GlobalData projects the Psoriasis market in 8MM to experience modest growth during the forecast period at a CAGR of 7.26%. This growth will be driven primarily by the highly anticipated arrivals of promising systemic therapies- interleukin-17 (IL-17) inhibitors (Cosentyx, guselkumab and tildrakizumab), interleukin-23 (IL-23) inhibitors (ixekizumab and brodalumab) as well as phsophodiesterase (PDE4) inhibitor- Otezla (apremilast). Nevertheless, looming patent expiries of high-grossing branded drugs- especially TNF inhibitors, Humira, Enbrel and Remicade, in the US, 5EU (France, Germany, Italy, Spain, UK), and Japan, along with rapid global developmentsof biosimilars are expected to spread the growth throughout the different classes of products, away from the branded TNF inhibitors which have traditionally been the main driver of growth in the prior years.

The US is the largest psoriasis market, although it does not have the highest diagnosed prevalence rates of psoriasis. The US will experience major brand erosion beginning with Humira in 2016, followed by Remicade in 2018 and Stelara in 2023; Enbrel is protected until 2028. Biosimilars are likely to launch in 2016 for adalimumab and will take some patient share away from Humira. Although biosimilar uptake will be favored for its cost effectiveness, unclear requirements for demonstrating interchangeability with originator biologics, as well as strong preferences for originator products among dermatologists, could be hindering factors.

Scope

  • Overview of Psoriasis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in the US from 2014-2024.
  • Analysis of the impact of key events as well the drivers and restraints affecting the US Psoriasis market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Psoriasis.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2014-2024 in US.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Leading Prescribed Drugs and Treatment Guidelines
    • 4.1.3. Clinical Practice
  • 4.2. US

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles - Major Brands
    • 5.3.1. Enbrel (Etanercept)
    • 5.3.2. Humira (Adalimumab)
    • 5.3.3. Remicade (Infliximab)
    • 5.3.4. Stelara (ustekinumab)
    • 5.3.5. Cosentyx (Secukinumab)
    • 5.3.6. Otezla (Apremilast)
    • 5.3.7. Taclonex and Enstilar (Calcipotriene and Betamethasone Dipropionate)
    • 5.3.8. Methotrexate
    • 5.3.9. Fumaderm (Fumaric Acid Esters)
    • 5.3.10. Alzumab (itolizumab)
    • 5.3.11. Other Therapeutic Drug Classes Used in Psoriasis
    • 5.3.12. Non-pharmacological Therapy

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Limited Patient Access Due to Drug Reimbursement Pattern
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Improved Drug Safety and Efficacy Profiles
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Education and Treatment of Psychological Factors Accompanying Psoriasis
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Physician Education About the Different Types of Psoriasis, not Just Plaque Psoriasis
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Clinical Trial Mapping
    • 7.2.1. Clinical Trials by Country
  • 7.3. Clinical Trials by Phase and Trial Status
  • 7.4. Promising Drugs in Clinical Development
    • 7.4.1. Xeljanz (Tofacitinib)
    • 7.4.2. Ixekizumab (LY2439821)
    • 7.4.3. Brodalumab
    • 7.4.4. Guselkumab (CNTO-1959)
    • 7.4.5. Tildrakizumab
    • 7.4.6. Piclidenoson (CF-101)
    • 7.4.7. Additional Phase III Pipeline Products
    • 7.4.8. Phase II Pipeline Products
    • 7.4.9. Phase I Pipeline Products
  • 7.5. Biosimilar Pipeline Products
    • 7.5.1. Introduction
    • 7.5.2. Hospira's Inflectra Versus J&J's Remicade in Key Autoimmune Diseases
    • 7.5.3. Biosimilars in the Immunology Community
    • 7.5.4. By the Numbers: Biosimilars in Development
    • 7.5.5. The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry
    • 7.5.6. Uptake of Biosimilars for Psoriasis is Expected to Vary by Market
    • 7.5.7. Biosimilars Forecast

8. Market Outlook

  • 8.1. US
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Psoriasis Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Generic Erosion
    • 9.4.8. Pricing of Pipeline agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Author
    • 9.7.2. Reviewer
    • 9.7.3. Epidemiologist
    • 9.7.4. Global Director of Therapy Analysis and Epidemiology
    • 9.7.5. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Immune Cells Involved in Lesions
  • Table 2: Symptoms of Psoriasis
  • Table 3: Minimal Investigative Measures Required Before Prescribing Biologics for Psoriasis
  • Table 4: Top Three Biologics Prescribed for Moderate to Severe Psoriasis by Market, 2014
  • Table 5: Treatment Guidelines for Psoriasis
  • Table 6: Country Profile - US
  • Table 7: Leading Treatments for Psoriasis, 2015
  • Table 8: Product Profile - Enbrel
  • Table 9: Enbrel Pivotal Study I Outcomes at 3 and 6 Months
  • Table 10: Enbrel pivotal study II outcomes at 3 Months
  • Table 11: Long-Term Studies on Enbrel Efficacy in Treatment of Psoriasis
  • Table 12: Long-Term Safety Profile of Enbrel in the Treatment of Psoriasis
  • Table 13: Enbrel SWOT Analysis, 2015
  • Table 14: Global Sales Forecast ($m) for Enbrel, 2014-2024
  • Table 15: Product Profile - Humira
  • Table 16: Humira pivotal study outcomes at 16 weeks
  • Table 17: Humira SWOT Analysis, 2015
  • Table 18: Global Sales Forecast ($m) for Humira, 2014-2024
  • Table 19: Product Profile - Remicade
  • Table 20: Efficacy Results of RESTORE1 Trial of Remicade vs. MTX at Week 26
  • Table 21: Safety Results and AEs of RESTORE1 Trial of Remicade vs. MTX at Week 16
  • Table 22: Remicade SWOT Analysis, 2015
  • Table 23: Global Sales Forecast ($m) for Remicade, 2014-2024
  • Table 24: Product Profile - Stelara
  • Table 25: Stelara Pivotal Study Outcomes at Week 12
  • Table 26: Stelara SWOT Analysis, 2015
  • Table 27: Global Sales Forecast ($m) for Stelara, 2014-2024
  • Table 28: Product Profile - Cosentyx
  • Table 29: Efficacy Endpoints in Cosentyx Phase III ERASURE Study
  • Table 30: Efficacy End Points in Cosentyx Phase III FIXTURE study
  • Table 31: Cosentyx SWOT Analysis, 2015
  • Table 32: Global Sales Forecast ($m) for Cosentyx, 2014-2024
  • Table 33: Product Profile - Otezla
  • Table 34: Otezla Efficacy Results at Week 16 in Studies ESTEEM-1 and ESTEEM-2
  • Table 35: Otezla SWOT Analysis, 2015
  • Table 36: Global Sales Forecast ($m) for Otezla, 2014-2024
  • Table 37: Product Profile - Taclonex/Enstilar
  • Table 38: Taclonex Efficacy Outcomes from Pivotal Phase III Studies for Adult Scalp and Body Psoriasis.
  • Table 39: Taclonex/Enstilar SWOT Analysis, 2015
  • Table 40: Global Sales Forecast ($m) for Taclonex/Daivobet/Dovobet, 2014-2024
  • Table 41: Product Profile - Methotrexate
  • Table 42: Methotrexate SWOT Analysis, 2015
  • Table 43: Global Sales Forecast ($m) for Methotrexate, 2014-2024
  • Table 44: Product Profile - Fumaderm
  • Table 45: Fumaderm SWOT Analysis, 2015
  • Table 46: Global Sales Forecast ($m) for Fumaderm, 2014-2024
  • Table 47: Product Profile - Alzumab
  • Table 48: Alzumab SWOT Analysis, 2013
  • Table 49: Global Sales Forecast ($m) for Alzumab, 2014-2024
  • Table 50: Summary of Minor Therapeutic Drug Classes for Psoriasis, 2015
  • Table 51: Dosing Guidelines for Broadband Ultraviolet B
  • Table 52: Dosing Guidelines for Narrowband Ultraviolet B
  • Table 53: Overall Unmet Needs in Psoriasis - Current Level of Attainment
  • Table 54: Psoriasis - Clinical Trials by Phase and Status, 2015
  • Table 55: Psoriasis - Phase Pipeline, 2015
  • Table 56: Comparison of Therapeutic Classes in Development for Psoriasis, 2015
  • Table 57: Product Profile - Xeljanz
  • Table 58: Xeljanz SWOT Analysis, 2015
  • Table 59: Global Sales Forecast ($m) for Xeljanz, 2014-2024
  • Table 60: Product Profile - Ixekizumab
  • Table 61: Efficacy Results of UNCOVER-2 at Week 12
  • Table 62: Efficacy Results of UNCOVER-3 at Week 12
  • Table 63: Ixekizumab SWOT Analysis, 2015
  • Table 64: Global Sales Forecast ($m) for Ixekizumab, 2014-2024
  • Table 65: Product Profile - Brodalumab
  • Table 66: Brodalumab SWOT Analysis, 2015
  • Table 67: Global Sales Forecast ($m) for Brodalumab, 2014-2024
  • Table 68: Product Profile - Guselkumab
  • Table 69: Guselkumab SWOT Analysis, 2015
  • Table 70: Global Sales Forecast ($m) for Guselkumab, 2014-2024
  • Table 71: Product Profile - Tildrakizumab
  • Table 72: Tildrakizumab SWOT Analysis, 2015
  • Table 73: Global Sales Forecast ($m) for Tildrakizumab, 2014-2024
  • Table 74: Product Profile - Piclidenoson (CF-101)
  • Table 75: Piclidenoson SWOT Analysis, 2015
  • Table 76: Additional Phase III Psoriasis Pipeline drugs, 2015
  • Table 77: Phase II Psoriasis Pipeline, 2015
  • Table 78: Phase I Psoriasis Pipeline, 2015
  • Table 79: Marketed and Pipeline Biosimilars for Psoriasis in the 8MM, 2015
  • Table 80: Physician Uptake of Biosimilar Products for Psoriasis Across the 8MM, 2015
  • Table 81: Global Sales Forecast ($m) for Etanercept Biosimilars, 2014-2024
  • Table 82: Global Sales Forecast ($m) for Adalimumab Biosimilars, 2014-2024
  • Table 83: Global Sales Forecast ($m) for Infliximab Biosimilars, 2014-2024
  • Table 84: Sales Forecast ($) for Psoriasis in the US, 2014-2024
  • Table 85: Key Events Impacting Sales for Psoriasis in the US, 2014-2024
  • Table 86: Psoriasis Market in the US - Drivers and Barriers, 2014-2024
  • Table 87: Key Launch Dates
  • Table 88: Key Patent Expiries
  • Table 89: Key Launch Dates
  • Table 90: Physicians Surveyed, by Country

List of Figures

  • Figure 1: Psoriatic Plaque on Elbow of Patient
  • Figure 2: The Three Layers of the Skin and Associated Structures
  • Figure 3: Healthy Skin Versus Psoriatic Skin
  • Figure 4: Psoriasis Therapeutics - Ongoing Clinical Trial Sites by Country, 2015
  • Figure 5: Competitive Assessment of Late-Stage Pipeline Agents in Psoriasis, 2014-2024
  • Figure 6: Biosimilar Prescribing Habits in Psoriasis Across the 8MM, 2015
  • Figure 7: Global Sales Forecast ($m) for Enbrel vs. Etanercept Biosimilars, 2014-2024
  • Figure 8: Global Sales Forecast ($m) for Humira vs. Adalimumab Biosimilars, 2014-2024
  • Figure 9: Global Sales Forecast ($m) for Remicade vs. Infliximab Biosimilars, 2014-2024
  • Figure 10: Sales for Psoriasis in the US by Drug Class, 2014-2024
Back to Top